Orforglipron clinical trials
Also written LY3502970.
ClinicalTrials.gov finds 53 studies for orforglipron. How that becomes 53 here
Every study that search finds has been read, to see whether and how it gives orforglipron. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 53Found by its intervention search · See all 53 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 36 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 54Give orforglipron to participants
- −1Compare another treatment with it
- 53Test it: the count on this site
Get an email when these change. Save the orforglipron studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
53 studies that test it; most in 2023 (13)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 13 |
| 2024 | 10 |
| 2025 | 11 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 50 · Other 3
Eli Lilly and Company (50) · Massachusetts General Hospital (2) · University of Florida (1)
Often tested with
Tested in the same studies.
Simvastatin (1) · Digoxin (1) · Acetaminophen (1) · Semaglutide (1) · Tirzepatide (1)
Related medicines
As reviewed, each with the page that says it.
- One of GLP-1 receptor agonists source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8, 8 in phase 3
Studies that test orforglipron, phase 3 first.
- Feb 2027A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)Phase 3 · Eli Lilly and Company
- May 2027A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingPhase 3 · Eli Lilly and Company
- Aug 2027A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesPhase 3 · Eli Lilly and Company
- Aug 2027A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityPhase 3 · Eli Lilly and Company
- Aug 2027A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesPhase 3 · Eli Lilly and Company
- Sep 2027A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)Phase 3 · Eli Lilly and Company
- Sep 2027A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1Phase 3 · Eli Lilly and Company
- Sep 2027A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2Phase 3 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses orforglipron has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 53
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesRecruitingPhase 3Eli Lilly and CompanyNCT07668336Against dulaglutide in young people with type 2 diabetesWritten as OrforglipronReport a problem
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityRecruitingPhase 3Eli Lilly and CompanyNCT07794579To prevent obesity complications in people with overweightWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesRecruitingPhase 3Eli Lilly and CompanyNCT06672939Against placebo in teenagers with obesityWritten as OrforglipronReport a problem
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)RecruitingPhase 3Eli Lilly and CompanyNCT06672549Against placebo in children and teenagers with obesityWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)RecruitingPhase 3Eli Lilly and CompanyNCT07241390Against placebo on heart and kidney outcomesWritten as OrforglipronReport a problem
- A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightRecruitingPhase 3Eli Lilly and CompanyNCT07202884Against placebo for stress urinary incontinence with obesityWritten as OrforglipronReport a problem
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseRecruitingPhase 3Eli Lilly and CompanyNCT07223593Against placebo in peripheral artery diseaseWritten as OrforglipronReport a problem
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaRecruitingPhase 2University of FloridaNCT07107334One possible GLP-1 drug with a hormonal IUD for endometrial neoplasiaReport a problem
- A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNot yet recruitingPhase 3Eli Lilly and CompanyNCT07790861Against placebo for weight loss in Chinese adultsWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingRecruitingPhase 3Eli Lilly and CompanyNCT07613307In type 2 diabetes during Ramadan fastingWritten as OrforglipronReport a problem
- PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesNot yet recruitingPhase 4Massachusetts General HospitalNCT07739537A short course to study responses to food by genotypeWritten as OrforglipronReport a problem
- Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationNot yet recruitingPhase 4Massachusetts General HospitalNCT07729332Against phentermine to keep weight off after GLP-1 injectionsWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminCompletedPhase 3Eli Lilly and CompanyNCT06192108Against dapagliflozin in type 2 diabetesWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeActive, not recruitingPhase 3Eli Lilly and CompanyNCT07153471Against placebo for knee osteoarthritis pain with obesityWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorCompletedPhase 3Eli Lilly and CompanyNCT06109311Added to insulin glargine, against placebo, in type 2 diabetesWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminCompletedPhase 3Eli Lilly and CompanyNCT06045221Against oral semaglutide in type 2 diabetesWritten as OrforglipronReport a problem
- A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT06649045Against placebo in sleep apnoea with obesityWritten as OrforglipronReport a problem
- A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT05872620Against placebo for weight loss in type 2 diabetesWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneCompletedPhase 3Eli Lilly and CompanyNCT05971940Against placebo in type 2 diabetes on diet and exerciseWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesActive, not recruitingPhase 3Eli Lilly and CompanyNCT05869903Against placebo for weight lossWritten as OrforglipronReport a problem
See all 53 studies that test orforglipron →
Tested on its own · 44 — no other medicine in its arm
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesRecruitingPhase 3Eli Lilly and CompanyNCT07668336Against dulaglutide in young people with type 2 diabetesWritten as OrforglipronReport a problem
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityRecruitingPhase 3Eli Lilly and CompanyNCT07794579To prevent obesity complications in people with overweightWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesRecruitingPhase 3Eli Lilly and CompanyNCT06672939Against placebo in teenagers with obesityWritten as OrforglipronReport a problem
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)RecruitingPhase 3Eli Lilly and CompanyNCT06672549Against placebo in children and teenagers with obesityWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)RecruitingPhase 3Eli Lilly and CompanyNCT07241390Against placebo on heart and kidney outcomesWritten as OrforglipronReport a problem
- A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightRecruitingPhase 3Eli Lilly and CompanyNCT07202884Against placebo for stress urinary incontinence with obesityWritten as OrforglipronReport a problem
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseRecruitingPhase 3Eli Lilly and CompanyNCT07223593Against placebo in peripheral artery diseaseWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNot yet recruitingPhase 3Eli Lilly and CompanyNCT07790861Against placebo for weight loss in Chinese adultsWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingRecruitingPhase 3Eli Lilly and CompanyNCT07613307In type 2 diabetes during Ramadan fastingWritten as OrforglipronReport a problem
- PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesNot yet recruitingPhase 4Massachusetts General HospitalNCT07739537A short course to study responses to food by genotypeWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminCompletedPhase 3Eli Lilly and CompanyNCT06192108Against dapagliflozin in type 2 diabetesWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeActive, not recruitingPhase 3Eli Lilly and CompanyNCT07153471Against placebo for knee osteoarthritis pain with obesityWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorCompletedPhase 3Eli Lilly and CompanyNCT06109311Added to insulin glargine, against placebo, in type 2 diabetesWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminCompletedPhase 3Eli Lilly and CompanyNCT06045221Against oral semaglutide in type 2 diabetesWritten as OrforglipronReport a problem
- A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT06649045Against placebo in sleep apnoea with obesityWritten as OrforglipronReport a problem
- A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT05872620Against placebo for weight loss in type 2 diabetesWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneCompletedPhase 3Eli Lilly and CompanyNCT05971940Against placebo in type 2 diabetes on diet and exerciseWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesActive, not recruitingPhase 3Eli Lilly and CompanyNCT05869903Against placebo for weight lossWritten as OrforglipronReport a problem
- A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesActive, not recruitingPhase 3Eli Lilly and CompanyNCT06993792Several doses against placebo, with and without type 2 diabetesWritten as OrforglipronReport a problem
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityActive, not recruitingPhase 3Eli Lilly and CompanyNCT06972459Several doses against placebo for weight lossWritten as OrforglipronReport a problem
Showing 20 of 44. See all 44 →
Tested with established drugs · 6 — they are given beside it
- A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06370728Its levels with and without carbamazepineWritten as OrforglipronReport a problem
- A Study of LY3502970 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03929744Single and repeated doses in healthy volunteersWritten as LY3502970Report a problem
- A Multiple Dose Study of LY3502970 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05051566A new formulation compared in healthy volunteersWritten as LY3502970Report a problem
- A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05469126Its levels with and without clarithromycinWritten as LY3502970Report a problem
- A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05573230Its levels with and without cyclosporineWritten as LY3502970Report a problem
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06704763Its levels with and without quinidineWritten as OrforglipronReport a problem
Tested in a combination · 3 — another drug in the study is under test too
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaRecruitingPhase 2University of FloridaNCT07107334One possible GLP-1 drug with a hormonal IUD for endometrial neoplasiaReport a problem
- Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationNot yet recruitingPhase 4Massachusetts General HospitalNCT07729332Against phentermine to keep weight off after GLP-1 injectionsWritten as OrforglipronReport a problem
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06186622Its effect on five other drugs' levelsWritten as OrforglipronReport a problem
As the comparator · 1 — what is tested is compared with orforglipron
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call orforglipron · ClinicalTrials.gg INT002055
- MeSH (NLM) C000729680orforglipronConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7ZW40D021MORFORGLIPRONConfirmed FDA, NLM, Wikidata
- Wikidata Q120491908orforglipronConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C199084OrforglipronOne source FDA
- DrugBank DB18964One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729680 | orforglipron | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7ZW40D021M | ORFORGLIPRON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q120491908 | orforglipron | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C199084 | Orforglipron | One source FDA |
| DrugBank | DB18964 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.